A Global Overview of Precision Medicine in Type 2 Diabetes.

Diabetes
Authors
Keywords
Abstract

The detailed characterization of human biology and behaviors is now possible at scale owing to innovations in biomarkers, bioimaging, and wearable technologies; "big data" from electronic medical records, health insurance databases, and other platforms becoming increasingly accessible; and rapidly evolving computational power and bioinformatics methods. Collectively, these advances are creating unprecedented opportunities to better understand diabetes and many other complex traits. Identifying hidden structures within these complex data sets and linking these structures to outcome data may yield unique insights into the risk factors and natural history of diabetes, which in turn may help optimize the prevention and management of the disease. This emerging area is broadly termed "precision medicine." In this Perspective, we give an overview of the evidence and barriers to the development and implementation of precision medicine in type 2 diabetes. We also discuss recently presented paradigms through which complex data might enhance our understanding of diabetes and ultimately our ability to tackle the disease more effectively than ever before.

Year of Publication
2018
Journal
Diabetes
Volume
67
Issue
10
Pages
1911-1922
Date Published
2018 10
ISSN
1939-327X
DOI
10.2337/dbi17-0045
PubMed ID
30237159
PubMed Central ID
PMC6152339
Links
Grant list
K24 DK110550 / DK / NIDDK NIH HHS / United States
R01 DK072041 / DK / NIDDK NIH HHS / United States
U01 DK105535 / DK / NIDDK NIH HHS / United States
106130 / Wellcome Trust / United Kingdom
U01 DK105554 / DK / NIDDK NIH HHS / United States
R01 DK105154 / DK / NIDDK NIH HHS / United States
203141 / Wellcome Trust / United Kingdom
Wellcome Trust / United Kingdom
R01 GM117163 / GM / NIGMS NIH HHS / United States
098381 / Wellcome Trust / United Kingdom